Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance

Reuters09-12

<a href="https://laohu8.com/S/LPTX">Leap Therapeutics Inc</a>. Faces Nasdaq Delisting Risk Over Stock Price Compliance

Leap Therapeutics Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566991185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566991185","market":"us","top_or_hot":-1,"title":"Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 04:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL1tSqj6:1","article_id":"2566991185","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566991185","pubTimestamp":1757622705,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Leap Therapeutics Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550. As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4563":"昨日强势股","BK4139":"生物科技"},"translate_title":"Leap Therapeutics Inc.因股价合规面临纳斯达克退市风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LPTX":0.9},"content_text":"Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n    \n\n        Leap Therapeutics Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566991185","isCrawlerRequest":true}